Abstract 784P
Background
Choriocarcinoma (CC) is a rare and highly aggressive cancer that exists in both the gestational (GCC) and non-gestational (NGCC) forms. Our research focused on comparing clinical outcomes, response to therapy, and prognostic determinants between these subtypes.
Methods
We analyzed data from the SEER database of patients diagnosed with CC between 2000 and 2020. Patients who were not diagnosed based on histology, previous history of cancer or other concurrent malignancies, or unknown data were excluded. The chi-square test were used for clinical features comparison. Kaplan-Meier estimation, log-rank tests, and Cox regression analyses were used to identify prognostic factors for overall survival (OS) and cancer specific survival (CSS). A nomogram was developed to predict 5-year OS, and a calibration curve was plotted to evaluate the agreement between the actual (observed) outcomes and expected probabilities.
Results
Of the 719 patients studied, 520 had GCC, and 200 had NGCC. Younger individuals were more common in the GCC. Additionally, a higher percentage of patients with NGCC were married (63.0% vs. 52.6%). AJCC stage distribution also differed; 47.4% of GCC patients were at stage I compared to 6.0% of NGCC patients. The surgery rates were higher in the NGCC group (79.5% vs. 60.9%). Patients with GCC had better OS than those with NGCC (93% vs. 71.2%, p = 0.001). CSS rates were 66.8% for NGCC and 65.2% for GCC (p = 0.001).
We developed a prognostic nomogram that integrated significant variables from multivariate analysis. For GCC, the model assigned the highest weight to radiation, followed by metastasis, and marital status. The AUC was 0.711 (95% CI: 0.64–0.79), and the calibration curves exhibited a mean error of 0.015. The NGCC model assigned the highest weights to metastasis, chemotherapy, and age. The AUC was 0.837 (95% CI, 0.77–0.9), and the calibration curve for 5-year survival demonstrated a mean error of 0.01.
Conclusions
Our study highlights the significant clinical and survival differences between GCC and NGCC patients. We developed prognostic nomograms tailored to each subtype to enhance prediction and support personalized management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
761P - Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies
Presenter: Bastian Czogalla
Session: Poster session 02
762P - First results from phase II dose expansion cohort of transcon IL-2 β/γ in combination with standard of care chemotherapy for platinum resistant ovarian cancer (PROC) in the IL Believe trial
Presenter: Oladapo Yeku
Session: Poster session 02
763P - Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance
Presenter: Pamela Soberanis Pina
Session: Poster session 02
765P - HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkers
Presenter: Dahye Lee
Session: Poster session 02
766P - A phase II trial of fuzuloparib in combination with apatinib vs. fuzuloparib alone for recurrent ovarian cancer (OC)
Presenter: Jianqing Zhu
Session: Poster session 02
767P - Ovarian cancer risk factors in relation to family history
Presenter: Guoqiao Zheng
Session: Poster session 02
768P - Reclassification and variant distribution in the GINECO GREAT study of ovarian cancer patients: Insights into HRD status
Presenter: Etienne Rouleau
Session: Poster session 02
770P - Neoadjuvant pembrolizumab in stage IV ovarian cancer: The phase II Neo-Pembro trial
Presenter: Lot Aronson
Session: Poster session 02
771P - Claudin-6 expression in primary and recurrent epithelial ovarian cancer: A potential therapeutic target for high-grade serous ovarian cancer
Presenter: Daisuke Shintani
Session: Poster session 02